Exchange: NASDAQ·Updated 06:57 PM EDT
CCCC logo

CCCCC4 Therapeutics Inc

$3.90
$0.14
(3.45%)
Today
Closed $3.92
$0.02
(0.51%)
After Hours
EarningsAug 6
Mkt Cap$448.9M
Vol3.01M
News
all
press releases
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.
Zacks
News Placeholder
More News
News Placeholder
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
News Placeholder
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
Zacks
News Placeholder
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Zacks
News Placeholder
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Zacks
News Placeholder
Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
Vishay Intertechnology (VSH) stock up 10%, Velo3D (VELO) up 35.5%, VNET (VNET) up 32.5%, C4 Therapeutics (CCCC) up 19.4%, Kingsoft Cloud (KC) up 18.6%, Tower Semiconductor (TSEM) up 17.5%, Nebius...
Benzinga
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +4.76% and -5.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -20.00% and +15.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Advertisement|Remove ads.